A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4200 participants.

Also called NCT06935370

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06935370
  • EU CT 2024-519525-38-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Serbia, Slovakia, South Korea, Spain, Taiwan, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06935370. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-20 (actual); primary completion 2029-02-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Condition
Heart Failure
Intervention (Drug)
vicadrostat
Intervention (Drug)
empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct06935370
Content hash
fe83661dbd2fa8ffc97497c2270f67d173d316340ed6abd376f869fc990a6518